Biotech News
Callio Therapeutics Launches with $187M to Develop Next-Gen ADC Cancer Therapies
Callio Therapeutics, a biotechnology company focused on developing multi-payload antibody-drug conjugates (ADCs) for cancer therapy, has launched with the closing of a $187 million Series A financing round. The investment was led by Frazier Life Sciences, with participation from Jeito
4 March 2025